Genetic Technologies Limited's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2024 to a ratio of 73.14, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the fourth quarter 2024. Average receivable collection period, for the Genetic Technologies Limited in Jun 30 2024 quarter, has decreased to 5 days, compared to 1460 days, in the 0 quarter.

If we take a look into Healthcare sector 57 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2024 from to 718.

What is Receivable Turnover Ratio?
What is Genetic Technologies Limited Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GENE Receivables Turnover Ratio	(Jun 30 2024) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2019) IV. Quarter
Y / Y Receivable Change	9.27 %	-	-54.24 %	-	90.69 %
Y / Y Revenue Change	30024.13 %	-	-	-	-86.56 %
Receivable Turnover Ratio (TTM)	73.14	0.25	0.38	0.23	0.23
GENE's Total Ranking	# 718	#	#	#	#
Accounts Receivable average collection period days	5	1461	960	1554	1554
Seq. Receivable Change	0 %	0 %	-	-	-
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 2
Healthcare Sector	# 58
Overall Market	# 718

Receivable Turnover Ratio Statistics
High	Average	Low
1.22	0.46	0
(Jun 30 2024)		(Jun 30 2021)

GENE Company Profile • Back to GENE Efficiency Comparisons • Compare GENE Receivables Turnover Ratio to its Competitors

Financial Statements
Genetic Technologies Limited's Accounts Receivable	$ 0 Millions	Visit GENE's Balance sheet
Genetic Technologies Limited's Sales TTM	$ 8 Millions	Visit GENE's Income Statement
Sources of GENE's Revenues		Visit GENE's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GENE's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GENE's Growth Rates	GENE's Roa	GENE's Inventory Turnover Ratio	GENE's Dividend Comparisons
GENE's Profitability Ratios	GENE's Roi	GENE's Asset Turnover Ratio	GENE's Dividend Growth
GENE's Valuation Ratios	GENE's Roe	GENE's Financial Strength Ratios	GENE's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2024, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2024	Receivable at quarter ending Jun 30 2024
Logicmark Inc	131.04	$ 9.740 Millions	$ 0.074 Millions
Earth Science Tech Inc	129.16	$ 19.889 Millions	$ 0.154 Millions
Nurix Therapeutics Inc	124.61	$ 62.303 Millions	$ 0.500 Millions
Healthlynked Corp	120.74	$ 4.063 Millions	$ 0.034 Millions
Orthofix Medical Inc	99.47	$ 770.509 Millions	$ 7.746 Millions
Aclaris Therapeutics Inc	95.43	$ 32.016 Millions	$ 0.336 Millions
Lifevantage Corp	86.84	$ 199.724 Millions	$ 2.300 Millions
Prothena Corporation Public Limited Company	84.22	$ 217.246 Millions	$ 2.580 Millions
Marpai Inc	77.56	$ 31.814 Millions	$ 0.410 Millions
Mersana Therapeutics inc	76.27	$ 29.937 Millions	$ 0.393 Millions
Precision Biosciences Inc	70.00	$ 87.640 Millions	$ 1.252 Millions
Brookdale Senior Living Inc	62.91	$ 3,072.146 Millions	$ 48.835 Millions
Safe Pro Group Inc	62.16	$ 0.643 Millions	$ 0.010 Millions
Harvard Apparatus Regenerative Technology Inc	61.71	$ 0.216 Millions	$ 0.003 Millions
Fonar Corporation	56.03	$ 102.884 Millions	$ 1.836 Millions
Cervomed Inc	55.85	$ 12.781 Millions	$ 0.229 Millions
Lucid Diagnostics Inc	55.27	$ 3.800 Millions	$ 0.069 Millions
Caribou Biosciences Inc	54.89	$ 33.113 Millions	$ 0.603 Millions
Agape Atp Corporation	53.77	$ 1.378 Millions	$ 0.026 Millions
Vireo Growth Inc.	48.26	$ 98.044 Millions	$ 2.031 Millions
Adaptimmune Therapeutics Plc	45.82	$ 141.459 Millions	$ 3.087 Millions
Nektar Therapeutics	45.32	$ 93.157 Millions	$ 2.056 Millions
Nature s Sunshine Products inc	44.96	$ 441.734 Millions	$ 9.826 Millions
Pavmed Inc	44.20	$ 4.232 Millions	$ 0.096 Millions
Xoma Royalty Corporation	38.68	$ 15.239 Millions	$ 0.394 Millions
Ginkgo Bioworks Holdings Inc	38.65	$ 184.335 Millions	$ 4.769 Millions
Dih Holding Us Inc	38.52	$ 112.297 Millions	$ 2.915 Millions
Pluri Inc	38.35	$ 0.326 Millions	$ 0.009 Millions
Vivos Therapeutics Inc	38.23	$ 12.904 Millions	$ 0.338 Millions
Eyepoint Inc	35.50	$ 50.391 Millions	$ 1.420 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.